Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, First-Time-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ecc0509 in Healthy Volunteers

NCT05012423 is registered in ClinicalTrials.gov with Eccogene as lead sponsor.

NCT NCT05012423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05012423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, First-Time-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ecc0509 in Healthy Volunteers
Lead sponsor
Eccogene
Phase
Phase 1
Overall status
Completed
Start date
July 26, 2021
Completion date
July 22, 2023
Enrollment
89 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic steatohepatitis, osteoarthritis